Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Tests a shorter radiation boost plus pelvic radiation for high-risk prostate cancer

Tests a radiation boost to the prostate in men with prostate cancer.

Plain-language title generated from the registry record
Registry title: Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

Key facts

Where
Toronto, CanadaSee the site

Where in Canada

  • Princess Margaret Cancer CenterToronto, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Health Network, Toronto
Trial code
NCT05313815
Record updated
5 June 2026
Original description
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiotherapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.Read full original descriptionShow less

Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiotherapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.

Inclusion: Age > 18 years; Able to provide informed consent; Histologic diagnosis of prostate adenocarcinoma; ECOG performance status 0-1; High-risk localized disease by NCCN criteria (>cT3, Grade group >4, or PSA >20 ng/mL) or clinical N1 disease; Clinical M0 by conventional imaging (computed tomography (CT) and bone scan (BS)) and/or molecular imaging (prostate specific membrane antigen (PSMA)- positron emission tomography (PET)).

Exclusion: Prior pelvic radiotherapy; Contraindications to radiotherapy.

ClinicalTrials.gov NCT05313815